Browsing by Author "Chiong, Mario"
Now showing 1 - 20 of 48
Results Per Page
Sort Options
- ItemÁcido úrico: una molécula con acciones paradójicas en la insuficiencia cardiaca(2011) Alcaíno, Hernán; Greig, Douglas; Castro Gálvez, Pablo Federico; Verdejo Pinochet, Hugo; Mellado Suazo, Rosemarie; García, Lorena; Díaz Araya, Guillermo; Quiroga Lagos, Clara Rosa; Chiong, Mario; Lavandero, Sergio
- ItemAcute effect of iloprost inhalation on right atrial function and ventricular dyssynchrony in patients with pulmonary artery hypertension(2017) Gabrielli, Luigi; Ocaranza, María Paz; Sitges, Marta; Kanacri, Andrés; Saavedra Madariaga, Rodrigo Alejandro; Sepúlveda Varela, Pablo Andrés; Sepúlveda, Luis; Rossel, Víctor; Zagolin, Mónica; Verdejo Pinochet, Hugo; Baraona Reyes, Fernando Exequiel; Zalaquett Sepúlveda, Ricardo; Chiong, Mario; Lavandero, Sergio; Castro Gálvez, Pablo Federico
- ItemAngiotensin II-Regulated Autophagy Is Required for Vascular Smooth Muscle Cell Hypertrophy(2019) Mondaca-Ruff, David; Riquelme, Jaime A.; Quiroga Lagos, Clara Rosa; Norambuena-Soto, Ignacio; Sanhueza-Olivares, Fernanda; Villar-Fincheira, Paulina; Hernández-Díaz,Tomás; Cancino-Arenas, Nicole; San Martín, Alejandra; García, Lorena; Lavandero, Sergio; Chiong, Mario
- ItemAngiotensin-(1-9) reduces cardiovascular and renal inflammation in experimental renin-independent hypertension(2018) Gonzalez, Leticia; Novoa, Ulises; Moya, Jackeline; Gabrielli, Luigi; Jalil Milad, Jorge; Garcia, Lorena; Chiong, Mario; Lavandero, Sergio; Paz Ocaranza, Maria
- ItemAngiotensin-(1-9) regulates cardiac hypertrophy in vivo and in vitro(LIPPINCOTT WILLIAMS & WILKINS, 2010) Paz Ocaranza, Maria; Lavandero, Sergio; Jalil, Jorge E.; Moya, Jaqueline; Pinto, Melissa; Novoa, Ulises; Apablaza, Felipe; Gonzalez, Leticia; Hernandez, Carol; Varas, Manuel; Lopez, Rene; Godoy, Ivan; Verdejo, Hugo; Chiong, MarioBackground Angiotensin-(1-9) is present in human and rat plasma and its circulating levels increased early after myocardial infarction or in animals treated with angiotensin-converting enzyme inhibitor. However, the cardiovascular effects of this peptide are unknown.
- ItemAT2 Receptor Mediated Activation of the Tyrosine Phosphatase PTP1B Blocks Caveolin-1 Enhanced Migration, Invasion and Metastasis of Cancer Cells(2019) Martínez-Meza, Samuel; Díaz, Jorge; Sandoval-Bórquez, Alejandra; Valenzuela-Valderrama, Manuel; Díaz-Valdivia, Natalia; Rojas-Celis, Victoria; Contreras, Pamela; Huilcaman, Ricardo; Ocaranza Jeraldino, María Paz; Chiong, Mario; Leyton, Lissette; Lavandero, Sergio; Quest, Andrew F. G.The renin-angiotensin receptor AT2R controls systemic blood pressure and is also suggested to modulate metastasis of cancer cells. However, in the latter case, the mechanisms involved downstream of AT2R remain to be defined. We recently described a novel Caveolin-1(CAV1)/Ras-related protein 5A (Rab5)/Ras-related C3 botulinum toxin substrate 1 (Rac1) signaling axis that promotes metastasis in melanoma, colon, and breast cancer cells. Here, we evaluated whether the anti-metastatic effect of AT2R is connected to inhibition of this pathway. We found that murine melanoma B16F10 cells expressed AT2R, while MDA-MB-231 human breast cancer cells did not. AT2R activation blocked migration, transendothelial migration, and metastasis of B16F10(cav-1) cells, and this effect was lost when AT2R was silenced. Additionally, AT2R activation reduced transendothelial migration of A375 human melanoma cells expressing CAV1. The relevance of AT2R was further underscored by showing that overexpression of the AT2R in MDA-MB-231 cells decreased migration. Moreover, AT2R activation increased non-receptor protein tyrosine phosphatase 1B (PTP1B) activity, decreased phosphorylation of CAV1 on tyrosine-14 as well as Rab5/Rac1 activity, and reduced lung metastasis of B16F10(cav-1) cells in C57BL/6 mice. Thus, AT2R activation reduces migration, invasion, and metastasis of cancer cells by PTP1B-mediated CAV1 dephosphorylation and inhibition of the CAV1/Rab5/Rac-1 pathway. In doing so, these observations open up interesting, novel therapeutic opportunities to treat metastatic cancer disease.
- ItemAutophagy and oxidative stress in non-communicable diseases: A matter of the inflammatory state?(2018) Pena-Oyarzun, Daniel; Bravo-Sagua, Roberto; Diaz-Vega, Alexis; Aleman, Larissa; Chiong, Mario; Garcia, Lorena; Bambs S., Claudia; Troncoso, Rodrigo; Cifuentes, Mariana; Morselli, Eugenia; Ferreccio Readi, Catterina; Quest, Andrew F. G.; Criollo, Alfred
- ItemBasal autophagy protects cardiomyocytes from doxorubicin-induced toxicity(2016) Pizarro, Marcela; Troncoso, Rodrigo; Martínez, Gonzalo; Chiong, Mario; Castro Gálvez, Pablo Federico
- Itembeta-Hydroxybutyrate Increases Exercise Capacity Associated with Changes in Mitochondrial Function in Skeletal Muscle(MDPI, 2020) Monsalves Alvarez, Matias; Morales, Pablo Esteban; Castro Sepulveda, Mauricio; Sepulveda, Carlos; Rodriguez, Juan Manuel; Chiong, Mario; Eisner, Veronica; Lavandero, Sergio; Troncoso, Rodrigobeta-hydroxybutyrate is the main ketone body generated by the liver under starvation. Under these conditions, it can sustain ATP levels by its oxidation in mitochondria. As mitochondria can modify its shape and function under different nutritional challenges, we study the chronic effects of beta-hydroxybutyrate supplementation on mitochondrial morphology and function, and its relation to exercise capacity. Male C57BL/6 mice were supplemented with beta-hydroxybutyrate mineral salt (3.2%) or control (CT, NaCl/KCl) for six weeks and submitted to a weekly exercise performance test. We found an increase in distance, maximal speed, and time to exhaustion at two weeks of supplementation. Fatty acid metabolism and OXPHOS subunit proteins declined at two weeks in soleus but not in tibialis anterior muscles. Oxygen consumption rate on permeabilized fibers indicated a decrease in the presence of pyruvate in the short-term treatment. Both the tibialis anterior and soleus showed decreased levels of Mitofusin 2, while electron microscopy assessment revealed a significant reduction in mitochondrial cristae shape in the tibialis anterior, while a reduction in the mitochondrial number was observed only in soleus. These results suggest that short, but not long-term, beta-hydroxybutyrate supplementation increases exercise capacity, associated with modifications in mitochondrial morphology and function in mouse skeletal muscle.
- ItemCirculating Vascular Cell Adhesion Molecule-1 (sVCAM-1) Is Associated With Left Atrial Remodeling in Long-Distance Runners(FRONTIERS MEDIA SA, 2021) Contreras Briceño, Felipe; Herrera, Sebastián; Vega Adauy, Julián; Salinas, Manuel; Ocaranza Jeraldino, María Paz; Jalil Milad, Jorge; Mandiola Ovalle, Jorge; García, Lorena; Chiong, Mario; Castro Galvez, Pablo Federico; Lavandero, Sergio; Gabrielli Nervi, Luigi ArnaldoIntroduction: An increased risk of atrial fibrillation (AF) has been demonstrated in high-performance athletes. Soluble vascular adhesion molecule-1 (sVCAM-1), a biomarker involved in inflammation and cardiac remodeling, is associated with the development of AF in the general population. However, the relationship between sVCAM-1 and left atrial (LA) remodeling has been poorly investigated in long-distance runners (LDR).Aim: To determine the association between LA remodeling and sVCAM-1 levels in LDR during the training period before a marathon race.Methods: Thirty-six healthy male LDR (37.0 +/- 5.3 years; 174.0 +/- 7.0 height; BMI: 23.8 +/- 2.8; V degrees O-2-peak: 56.5 +/- 7.3 mL center dot kg(-1)center dot min(-1)) were evaluated in this single-blind and cross-sectional study. The LDR were separated into two groups according to previous training levels: high-training (HT) (n = 18) >= 100 km center dot week(-1) and low-training (LT) (n = 18) >= 70 and <100 km center dot week(-1). Also, 18 healthy non-active subjects were included as a control group (CTR). In all participants, transthoracic echocardiography was performed. sVCAM-1 blood levels were measured baseline and immediately finished the marathon race in LDR.Results: HT showed increased basal levels of sVCAM-1 (651 +/- 350 vs. 440 +/- 98 ng center dot mL(-1) CTR, p = 0.002; and vs. 533 +/- 133 ng center dot mL(-1) LT; p = 0.003) and a post-marathon increase (Delta sVCAM-1) (651 +/- 350 to 905 +/- 373 ng center dot mL(-1); p = 0.002), that did not occur in LT (533 +/- 133 to 651 +/- 138 ng center dot mL(-1); p = 0.117). In LDR was a moderate correlation between LA volume and sVCAM-1 level (rho = 0.510; p = 0.001).Conclusions: In male long-distance runners, sVCAM-1 levels are directly associated with LA remodeling. Also, the training level is associated with basal sVCAM-1 levels and changes after an intense and prolonged exercise (42.2 km). Whether sVCAM-1 levels predict the risk of AF in runners remains to be established.
- ItemComposición farmacéutica que comprende angiotensina (1-9) o sus derivados, composición farmacéutica que comprende un vector que sobreexpresa la enzima convertidora de angiotensina-I homologa (ECA2), útil para prevenir, revertir, inhibir y/o dismunir el remodelado cardiovascular, pulmonar, renal y/o cerebral (Chile, concesión n° 52291)Ocaranza, María Paz; Lavandero González, Sergio; Jalil Milad, Jorge; Chiong, Mario
- ItemComposición farmacéutica que contiene angiotensina-(1-9), para tratamiento cardiovascular, pulmonar y/o cerebral (Alemania, concesión n° 602009027372.8)Ocaranza, María Paz; Lavandero González, Sergio; Jalil Milad, Jorge; Chiong, Mario
- ItemComposición farmacéutica que contiene angiotensina-(1-9), para tratamiento cardiovascular, pulmonar y/o cerebral (España, concesión n° 2377544)Ocaranza, María Paz; Lavandero González, Sergio; Jalil Milad, Jorge; Chiong, Mario
- ItemComposición farmacéutica que contiene angiotensina-(1-9), para tratamiento cardiovascular, pulmonar y/o cerebral (Francia, concesión n° 2377544)Ocaranza, María Paz; Lavandero González, Sergio; Jalil Milad, Jorge; Chiong, Mario
- ItemComposición farmacéutica que contiene angiotensina-(1-9), para tratamiento cardiovascular, pulmonar y/o cerebral (Italia, concesión n° 502015000004373)Ocaranza, María Paz; Lavandero González, Sergio; Jalil Milad, Jorge; Chiong, Mario
- ItemComposición farmacéutica que contiene angiotensina-(1-9), para tratamiento cardiovascular, pulmonar y/o cerebral (Reino Unido, concesión n° 2377544)Ocaranza, María Paz; Lavandero González, Sergio; Jalil Milad, Jorge; Chiong, Mario
- ItemComposición farmacéutica que contiene angiotensina-(1-9), para tratamiento cardiovascular, pulmonar y/o cerebral (USA, concesión n° US 9,132,164)Ocaranza, María Paz; Lavandero González, Sergio; Jalil Milad, Jorge; Chiong, Mario
- ItemCounter-regulatory renin–angiotensin system in cardiovascular disease(2019) Ocaranza, María Paz; Riquelme, Jaime A.; García, Lorena; Jalil Milad, Jorge; Chiong, Mario; Santos, Robson A. S.; Lavandero, Sergio
- ItemEffects of Trimetazidine on Right Ventricular Function and Ventricular Remodeling in Patients with Pulmonary Artery Hypertension: A Randomised Controlled Trial(2023) Verdejo, Hugo E. E.; Rojas, Adolfo; Lopez-Crisosto, Camila; Baraona, Fernando; Gabrielli, Luigi; Maracaja-Coutinho, Vinicius; Chiong, Mario; Lavandero, Sergio; Castro, Pablo F. F.Background: Pulmonary artery hypertension (PAH) is a chronic and progressive disease. Although current therapy has improved the disease prognosis, PAH has a poor survival rate. The key feature leading to disease progression and death is right ventricular (RV) failure. Methods and results: We assessed the role of trimetazidine, a fatty acid beta-oxidation (FAO) inhibitor, in right ventricular function, remodeling, and functional class in PAH patients, with a placebo-controlled double-blind, case-crossover trial. Twenty-seven PAH subjects were enrolled, randomized, and assigned to trimetazidine or placebo for three months and then reallocated to the other study arm. The primary endpoint was RV morphology and function change after three months of treatment. Secondary endpoints were the change in exercise capacity assessed by a 6 min walk test after three months of treatment and the change in pro-BNP and Galectin-3 plasma levels after three months. Trimetazidine use was safe and well-tolerated. After three months of treatment, patients in the trimetazidine group showed a small but significant reduction of RV diastolic area, and a substantial increase in the 6 min walk distance (418 vs. 438 mt, p = 0.023), without significant changes in biomarkers. Conclusions: A short course of trimetazidine is safe and well-tolerated on PAH patients, and it is associated with significant increases in the 6MWT and minor but significant improvement in RV remodeling. The therapeutic potential of this drug should be evaluated in larger clinical trials.
- ItemEnergy-preserving effects of IGF-1 antagonize starvation-induced cardiac autophagy(2012) Troncoso, Rodrigo; Vicencio, Jose Miguel; Parra, Valentina; Nemchenko, Andriy; Kawashima, Yuki; Del Campo, Andrea; Toro, Barbra; Battiprolu, Pavan K.; Aranguiz, Pablo; Chiong, Mario; Yakar, Shoshana; Gillette, Thomas G.; Hill, Joseph A.; Abel, Evan Dale; LeRoith, Derek; Lavandero, Sergio
- «
- 1 (current)
- 2
- 3
- »